Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2005

View Archived Issues

Roche reviews H1 developments

Rotigaptide: potential as a therapy for osteoporosis

OncoMed completes Series A financing

Novo Nordisk and Sangamo BioSciences enter agreement for ZFP technology

Novel PTP-1B inhibitor synthesized by Incyte

Good safety and pharmacokinetics of AEOL-10150 in ALS patients

COR-100140: Orally active MIF antagonist with preclinical efficacy in inflammatory diseases

Ostarine moves into phase II development for muscle wasting

MEK inhibitor AR-00241389 active in animal models of arthritis and IBS

Progenics updates findings on HIV entry inhibitor PRO-140

Progenics updates methylnaltrexone progress

MedImmune and VasGene to develop monoclonal antibodies for cancer

TAP and Ilyang sign licensing agreement for ilaprazole

Sanctura XR enters phase III program for overactive bladder

Applied NeuroSolutions submits pre-IDE for Alzheimer's disease test

Columbia completes lidocaine vaginal gel pharmacokinetics study

Bexxar receives Canadian approval

MorphoSys and Shionogi sign HuCAL technology license agreement

SCH-6: characterization of a potent anti-HCV agent

New 5-HT2C agonist shown to be a therapeutic candidate for obesity

SGL-0010: a novel orally active SGLT inhibitor for diabetes

NIH sponsors drug discovery group to discover mood disorder drugs

Dosing begins in Russian phase II study of Dimebon for Alzheimer's disease

Novel analgesic agents in early development

Adenosine A2A receptor antagonists for Parkinson's claimed in Kyowa Hakko patent

Novel agents for thrombotic disorders imparted by Daiichi

Studies confirm that prasugrel is effective in inhibiting platelet aggregation

Good antitumor response reported with lenalidomide/dexamethasone in multiple myeloma

Surinabant (SR-147778) shows promising results in various rodent models of ADHD

Partial agonist of alpha7nAChRs produces antidepressant effect in rodents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...